home |R&D |R&D History

R&D인스토리-인류건강을 위해 끊임없이 연구개발하여 초일류 의약그룹으로 도약합니다.
  • 1957

    Developed and launched “Norumo”,
    the first product

  • 1971

    Launched “Wonbi-D”, the ginseng nutritious tonic
    Exported “Wonbi-D” to Japan

  • 1986

    Established the Central Research Institute

  • 1992~1995
    1997. 12
    1998. 11

    Clinical trial for Ilaprazole
    Obtained the U.S. substance patent for Ilaprazole
    Obtained the Korean substance patent for Ilaprazole

  • 2001. 12

    2007. 05

    2007. 10

    2007. 12

    2008. 07

    2008. 11

    2008. 12

    2009. 03
    2009. 07
    2009. 12
    2011. 08

    2012. 07

    2012. 01

    2014. 02

    2014. 05

    2014. 06

    2014. 07

    2014. 08

    2015. 01

    2015. 02

    2015. 05

    2015. 06

    2015. 07

    2015. 10

    2015. 12

    2016. 02

    2016. 02

    2016. 03

    2016. 05

    2016. 05

    2016. 05

    2016. 05

    2016. 06

    2016. 07

    Entered into the license agreement with
    China’s Livzon Pharmaceutical for Ilaprazole
    Multinational phase 3 clinical trial for Ilaprazole
    (6 South East Asian countries)
    Completed the phase 2 clinical trial for Ilaprazole’s effect on reflux esophagitis in the United States
    Obtained the approval of the Ilaprazole sale in China
    Started the phase 1 clinical trial for radotinib (IY5511)
    Obtained the approval of Ilaprazole (the nation’s 14th new indigenous drug)
    Established the SIS Immunology Research Center
    (Jointly with Sook-myung Women's University -Ilyang Pharmaceutical - Samsung Seoul
    Hospital),Started the research into new cytokine
    and new peptide
    Obtained the U.S. patent for radotinib
    Started the phase 2 clinical trial for radotinib
    Launched the Ilaprazole (Noltec tab) (in Korea)
    Started the phase 3 clinical trial for radotinib,
    the primary treatment drug
    Ilyang submitted the influenza vaccine IND
    and phase 1 clinical trial IRB
    Obtained the approval of radotinib(the nation’s
    18th new indigenous drug: Supect)
    Government held “Transgovernmental Enterprise
    for Pandemic Influenza in Korea(TEPIK)” Contest In the Final Selection, a New Influenza Vaccine,
    H7N9 form, Selected as Research Project Respiratory Syncytial Virus(RSV) Treatment Substance Developed
    Supect, the Result of 24 month of Clinical Phase II Presented at the 19th EHA(European Hematology Association)
    General Hospital of Beijing, Presented a Paper of Noltec
    Noltec, First Time Published on Global Medical Journal “AP&T”
    MOU Signed with College of Medicine KOREA University Research and Institute for Industry Cooperation
    Initiation of clinical trial phase 1/2a for quadrivalent inactivated Influenza Vaccine (egg-based)
    SUPECT, early completion of multi-national/multi-center clinical trial phase 3
    Approved market authorization for IL-YANG Flu Vaccine Vial INJ.(Trivalent inactivated influenza vaccine)
    SUPECT, Clinical trial result presented at Autumn conference of the Korean Society of Hematology(KSH)
    “SUPECT” validated as a potential treatment for Acute Myeloid Leukemia(AML)
    Candidate material for New Drug confirms efficacy on “Ebola Virus”
    Discover potential “MERS Virus” treatment substance
    Initiated Phase III Clinical trial for Quadrivalent Influenza Vaccine
    Super leukemia treatment SUPECT approved for 1st line treatment
    SUPECT, Orally presented its Final Phase III Clinical Trial Results at
    2015 American Society of Hematology (ASH) Annual Meeting
    SUPECT, Launching Ceremony for 1st Line Therapy
    IL-YANG PHARM, MOU signed with Gyeongbuk Institute for Bio Industry
    SUPECT, Presented Phase III Clinical Trial Results at 2016 Highlight of ASH in Asia-Pacific (2016 HOA)
    IL-YANG, entered MOU with Cha Vaccine R&D Center for cooperate R&D of Flu Vaccines and other New Vaccines.
    Discovered an effective material for ‘Zika’ and ‘MERS’ virus treatment.
    Development of ‘Prion Diseases Treatment’ has been selected as research project of Ministry of Health and Welfare.
    New influenza vaccine research project finally selected as governments’ “Infectious diseases crisis management technology development“ contest.
    ‘H7N9 Vaccine’ Avian Influenza vaccine, presented at 35th American Society for Virology (ASV) Annual Meeting.
    Development of MERS virus treatment, selected as governmental research project